These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35224677)

  • 1. Evaluating outcomes associated with revised fluoroquinolone breakpoints for Enterobacterales urinary tract infections: A retrospective cohort study.
    Benavides TM; Aden JK; Giancola SE
    Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):741-749. PubMed ID: 35224677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT; Blondeau JM
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High fluoroquinolone MIC is associated with fluoroquinolone treatment failure in urinary tract infections caused by fluoroquinolone susceptible Escherichia coli.
    Rattanaumpawan P; Nachamkin I; Bilker WB; Roy JA; Metlay JP; Zaoutis TE; Lautenbach E;
    Ann Clin Microbiol Antimicrob; 2017 Apr; 16(1):25. PubMed ID: 28390438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for ambulatory urinary tract infections caused by high-MIC fluoroquinolone-susceptible Escherichia coli in women: results from a large case-control study.
    Rattanaumpawan P; Nachamkin I; Bilker WB; Roy JA; Metlay JP; Zaoutis TE; Lautenbach E;
    J Antimicrob Chemother; 2015 May; 70(5):1547-51. PubMed ID: 25630645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative
    Afriyie DK; Adu LB; Dzradosi M; Amponsah SK; Ohene-Manu P; Manu-Ofei F
    Pan Afr Med J; 2018; 30():194. PubMed ID: 30455823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance Patterns of Escherichia coli in Women with Uncomplicated Urinary Tract Infection Do Not Correlate with Emergency Department Antibiogram.
    Hines MC; Al-Salamah T; Heil EL; Mallemat H; Witting MD; Johnson JK; Winters ME; Hayes BD
    J Emerg Med; 2015 Dec; 49(6):998-1003. PubMed ID: 26281821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Impact of the Revised 2019 CLSI Levofloxacin Breakpoints in Patients with
    Huang HY; Wang CF; Lu PL; Tseng SP; Wang YL; Chen TC; Chang K; Tu HP; Lin SY
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33782006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoroquinolone susceptibility testing of Salmonella enterica: detection of acquired resistance and selection of zone diameter breakpoints for levofloxacin and ofloxacin.
    Sjölund-Karlsson M; Howie RL; Crump JA; Whichard JM
    J Clin Microbiol; 2014 Mar; 52(3):877-84. PubMed ID: 24391204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study.
    Wang J; Gagne JJ; Kattinakere-Sreedhara S; Fischer MA; Bykov K
    BMJ; 2022 Oct; 379():e069931. PubMed ID: 36195324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance of Fluoroquinolone Resistance in Wisconsin: Geographic Variation and Impact of Revised CLSI Breakpoints.
    Lazzerini G; Lavey SC; Fox BC; Munson E
    Clin Med Res; 2022 Jun; 20(2):81-88. PubMed ID: 35086853
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens.
    Chen YH; Ko WC; Hsueh PR
    Eur J Clin Microbiol Infect Dis; 2012 Aug; 31(8):1699-704. PubMed ID: 22052606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic prescribing patterns for adult urinary tract infections within emergency department and urgent care settings.
    Maddali N; Cantin A; Koshy S; Eiting E; Fedorenko M
    Am J Emerg Med; 2021 Jul; 45():464-471. PubMed ID: 33067064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Day versus 10-Day Course of Fluoroquinolones in Outpatient Males with a Urinary Tract Infection (UTI).
    Mospan GA; Wargo KA
    J Am Board Fam Med; 2016 Nov; 29(6):654-662. PubMed ID: 28076247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective review of ceftriaxone versus levofloxacin for treatment of E. coli urinary tract infections.
    Wang SS; Ratliff PD; Judd WR
    Int J Clin Pharm; 2018 Feb; 40(1):143-149. PubMed ID: 29147962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effectiveness of beta-lactams versus fluoroquinolones as empirical therapy in patients with diabetes mellitus hospitalized for urinary tract infections: A retrospective cohort study.
    Tang YH; Lu PL; Huang HY; Lin YC
    PLoS One; 2022; 17(3):e0266416. PubMed ID: 35358291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies.
    Grillon A; Schramm F; Kleinberg M; Jehl F
    PLoS One; 2016; 11(6):e0156690. PubMed ID: 27257956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for urinary tract infections due to ciprofloxacin-resistant Escherichia coli in a tertiary care urology department in Switzerland.
    Nicoletti J; Kuster SP; Sulser T; Zbinden R; Ruef C; Ledergerber B; Weber R
    Swiss Med Wkly; 2010; 140():w13059. PubMed ID: 20648400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with ciprofloxacin-resistant Escherichia coli urinary tract infections in discharged ED patients.
    Kratochwill L; Powers M; McGraw MA; King L; O'Neill JM; Venkat A
    Am J Emerg Med; 2015 Oct; 33(10):1473-6. PubMed ID: 26302942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H; Azap OK; Ergönül O; Timurkaynak F;
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis.
    Roberts MJ; Scott S; Harris PN; Naber K; Wagenlehner FME; Doi SAR
    World J Urol; 2018 Mar; 36(3):323-330. PubMed ID: 29288398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.